While the current MCR therapy market is dominated by high-value, niche indications, the emerging pipeline is positioned to expand the class into mainstream disorders....
While the current MCR therapy market is dominated by high-value, niche indications, the emerging pipeline is positioned to expand the class into mainstream disorders....
ORLANDO, Fla., July 14, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy Inc. (OTC: BLEG), a diversified holdings company, today announced significant changes in its leadership structure and a strategic merger initiative aimed at positioning the company for growth in the burgeoning addiction therapeutics sector.
DELRAY BEACH, Fla., July 14, 2025 /PRNewswire/ -- The report "Microcrystalline Cellulose Market by Source (Wood based, non-wood based), by Application (Food & Beverage,...
DELRAY BEACH, Fla., July 14, 2025 /PRNewswire/ -- The report "Microcrystalline Cellulose Market by Source (Wood based, non-wood based), by Application (Food & Beverage,...
DELRAY BEACH, Fla., July 11, 2025 /PRNewswire/ -- The global Botulinum Toxins Market, valued at US$8.1 billion in 2024 stood at US$8.9 billion in 2025...
DELRAY BEACH, Fla., July 11, 2025 /PRNewswire/ -- The global Botulinum Toxins Market, valued at US$8.1 billion in 2024 stood at US$8.9 billion in 2025...
BIEL, Switzerland and BERN, Switzerland, July 11, 2025 /PRNewswire/ -- As product requirements evolve, engineers and designers search for solutions that enable greater integration,...
The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline...
The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline...
London – 9 July 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PS-002, enabling the initiation of a Phase I/II clinical trial in patients with primary IgA nephropathy (IgAN).